Roche Backs Out Of Collaboration With Trimeris On Next-Generation Fusion Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Major management shake-up includes departure of Trimeris CEO.
You may also be interested in...
Maxygen Gets $90 Million Cash Infusion From Bayer For Hemophilia Program
Deal will build on Bayer’s hemophilia experience with Kogenate, and provide cash for Maxygen to explore autoimmune programs.
Maxygen Gets $90 Million Cash Infusion From Bayer For Hemophilia Program
Deal will build on Bayer’s hemophilia experience with Kogenate, and provide cash for Maxygen to explore autoimmune programs.
Roche/Maxygen Early-Stage HCV/HBV Candidate Faces Setback
MAXY-alpha has been put on clinical hold based on Phase I observations.